UNLABELLED Although hormone therapy protects against bone loss after menopause, currently it is not recommended once menopausal symptoms have subsided. We reviewed randomized clinical trials to quantify bone loss after stopping hormone therapy and summarize treatment options for women who discontinue hormone treatment. We conducted a search of MEDLINE and EMBASE for randomized, controlled trial...

In order to compare the effect of propylthiouracil (PTU) of Iran Hormone Co. and that of Dr. Herbrand KG, Germany, 28 patients with toxic goiter entered this study. Each patient received 200 mg PTU daily for the first 4 weeks and 50 mg daily thereafter. 17 patients received PTU from Iran Hormone (group 1) and 111 took PTU from Germany (group 2). T4, T3 and TSH by RIA and resine T3, uptake were ...

Inappropriate TSH hypersecretion was diagnosed in a 34 years old woman. Earlier she had been treated by ablative therapy for hyperthyroidism. The present diagnosis was based on elevated basal serum TSH levels despite elevated serum free thyroid hormone level. Her TSH responses to TRH (peak value 240 mu/I) was high. Her albumin and prealbumin levels were normal. The serum TBG level, alpha subuni...

OBJECTIVE According to the guidelines for metastatic breast cancer, hormone therapy for hormone receptor-positive metastatic breast cancer without life-threatening metastasis should be received prior to chemotherapy. Previous trials have investigated the sensitivity of chemotherapy for preoperative breast cancer based on the efficacy of neoadjuvant hormone therapy. In this retrospective study, ...